|Day Low/High||5.28 / 5.56|
|52 Wk Low/High||5.28 / 9.86|
North Korea puts a worrying wrinkle in the markets. We add to 2 portfolio positions.
Expenses rose, revenue was bloated by a deferred lump sum and cash and equivalents has declined.
The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,217,694 share decrease in total short interest for Inovio Pharmaceuticals Inc. , to 8,603,835, a decrease of 20.49% since 07/14/2017.
Five portfolio names report today. Here is what we have seen, and what two expect after the closing bell.
What are the chances of a Draghi dovish surprise? I wouldn't bet the farm on anything.
Jim Cramer says investors should step away from these near-term shenanigans and focus on the fundamentals.
Jim Cramer is bullish on Chevron, Universal Display, Dynavax Technologies, and Schlumberger.
We'll purchase more shares of Pixelworks and Inovio ahead of their quarterly results next week.
We made several trades and price target changes during a mixed week for the portfolio.
Sometimes, changing the price target is better than selling (or buying).
The portfolio has some high fliers and underperformers last week as we head into the heart of earnings season.
Identifying this week's bullish and bearish reversal patterns.
Investors in Inovio Pharmaceuticals Inc. saw new options begin trading today, for the September 15th expiration.
Sarepta Therapeutics, Inovio Pharmaceuticals and Mylan were among the biotech movers in premarket trading on July 20.
Vertex Pharmaceuticals, FibroGen and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading trading on July 19.
We brought a new name into the portfolio last week as the Fed's comments helped lift the market.
We made no trades during the holiday-shortened week, but added to our natural hedge today.
Exelixis, Omeros and Inovio Pharmaceuticals were among the biotech movers in premarket trading on July 10.
Inovio dMAb® product induces complete protection against lethal challenge with influenza A & B viruses in published preclinical study